Takeda to build 100 million euro dengue vaccine plant

Japan’s largest drug company, Takeda Pharmaceutical (TYO: 4502), will invest more than 100 million euros ($106 million) to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

Takeda has described its move as a major step forward in meeting unmet needs in prevention of dengue, which is the fastest spreading mosquito-borne viral disease.

Around 40% of the world’s population lives under the threat of the dengue virus, which causes an estimated 390 million infections and more than 20,000 deaths each year around the world in people of all ages.